C12N 2800/107
For mammalian
Official title: for mammalian
C12N2800/107 (For mammalian) appears on 244 US grants and 589 published applications in this corpus.
Search patents in C12N- Granted patents
- 244
- Published applications
- 589
- Assignees
- 387
- Inventors
- 1,411
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 1 |
| 2002 | 4 | 5 |
| 2003 | 9 | 4 |
| 2004 | 0 | 3 |
| 2005 | 2 | 2 |
| 2006 | 1 | 7 |
| 2007 | 3 | 14 |
| 2008 | 2 | 10 |
| 2009 | 1 | 6 |
| 2010 | 5 | 10 |
| 2011 | 6 | 12 |
| 2012 | 8 | 17 |
| 2013 | 9 | 8 |
| 2014 | 5 | 12 |
| 2015 | 13 | 23 |
| 2016 | 9 | 17 |
| 2017 | 13 | 20 |
| 2018 | 14 | 19 |
| 2019 | 14 | 21 |
| 2020 | 9 | 25 |
| 2021 | 12 | 27 |
| 2022 | 13 | 66 |
| 2023 | 18 | 93 |
| 2024 | 22 | 56 |
| 2025 | 25 | 59 |
| 2026 | 24 | 52 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and production of nicked closed-ended DNA vectors8 Sep 2026US 12,729,386 B2Generation Bio Co.
- Cell surface tag exchange (CSTE) system for tracing and manipulation of cells during recombinase mediated cassette exchange integration of nucleic acid sequences to engineered receiver cells28 Jul 2026US 12,692,511 B2Genovie AB
- Protease substrate, and polypeptide including protease cleavage sequence14 Jul 2026US 12,680,093 B2Chugai Seiyaku Kabushiki Kaisha
- Target-specific CRISPR mutant7 Jul 2026US 12,674,150 B2Toolgen Incorporated
- Virus-like particle16 Jun 2026US 12,655,388 B2Autolus Limited
- Intraluminal stents for treating benign prostatic hyperplasia1 Oct 2026US 2026/0297612 A1Rivermark Medical, Inc.
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
- Liver cell regeneration10 Sep 2026US 2026/0263504 A1Agency for Science, Technology and Research
- Compositions, Methods, And Systems For Targeting And Destabilizing RNA Transcripts (TNBC)3 Sep 2026US 2026/0256824 A1UTR Therapeutics Inc.
- Function-enhanced engineered ebna1 for protein expression in mammalian cells27 Aug 2026US 2026/0250327 A1Wuxi Biologics Ireland Limited
Most cited
By later US patents
- Enhancement of vascular function by modulation of endogenous nitric oxide production or activity126US 5,891,459 AThe Board of Trustees of the Leland Stanford Junior University · 1999
- DNA transfection system for the generation of infectious influenza virus91US 6,951,754 B2St. Jude Children?S Research Hospital · 2005
- Orthogonal Cas9 proteins for RNA-guided gene regulation and editing86US 9,587,252 B2President and Fellows of Harvard College · 2017
- Compositions and methods for delivery of agents for neuronal regeneration and survival50US 6,551,618 B2King's College · 2003
- Orthogonal Cas9 proteins for RNA-guided gene regulation and editing45US 10,329,587 B2President and Fellows of Harvard College · 2019